Carlert Sara, Lennernäs Hans, Abrahamsson Bertil
Pharmaceutical Development, AstraZeneca R&D, S-431 83 Mölndal, Sweden.
Department of Pharmacy, Uppsala University, Box 580, S-751 23 Uppsala, Sweden.
Eur J Pharm Sci. 2014 Mar 12;53:17-27. doi: 10.1016/j.ejps.2013.12.004. Epub 2013 Dec 15.
The aim of this work was to evaluate an in vitro-in silico approach for prediction of small intestinal crystalline precipitation and drug absorption of two weakly basic model BCS class II drugs, AZD0865 and mebendazole. The crystallization rates were investigated in an in vitro method using simulated gastric and intestinal media, and the result was modeled by using Classical Nucleation Theory (CNT). The effect of varying in vitro parameters (initial drug concentration, rate of mixing gastric and intestinal fluid, stirring and filtration) on the interfacial tension γ, being a key parameter in CNT, was investigated. The initial drug concentration had the most significant effect on γ for both substances tested, although γ is a fundamental parameter independent of concentration according to CNT. In the subsequent in silico prediction of drug absorption, by use of a Compartmental and Transit intestinal model, an empirical approach was used where γ was allowed to vary with simulated small intestinal concentrations. The in silico predictions were compared to published human in vivo plasma drug concentration data for different doses of AZD0865 and dog intestinal drug concentrations, amount precipitated in intestine and plasma concentrations for mebendazole. The results showed that lack of significant crystallization effects on absorption in man of the model drug AZD0865 up to doses of 4 mg/kg could be predicted which was in accordance with in vivo data. Mebendazole intestinal precipitation in canines was also well described by the model, where mean predicted amount precipitated was 136% (range 111-164%) of measured solid amount, and mean predicted intestinal concentration was 94% (range 59-147%) of measured concentration. In conclusion, the in vitro-in silico approach can be used for predictions of absorption effects of crystallization, but the model could benefit from further development work on the theoretical crystallization model and in vitro experimental design.
本研究旨在评估一种体外-计算机模拟方法,用于预测两种弱碱性BCS II类模型药物AZD0865和甲苯达唑的小肠结晶沉淀及药物吸收情况。采用模拟胃和肠介质的体外方法研究结晶速率,并使用经典成核理论(CNT)对结果进行建模。研究了体外参数(初始药物浓度、胃和肠液混合速率、搅拌和过滤)对界面张力γ(CNT中的关键参数)的影响。尽管根据CNT,γ是一个与浓度无关的基本参数,但初始药物浓度对所测试的两种物质的γ影响最为显著。在随后的药物吸收计算机模拟预测中,通过使用房室和转运肠道模型,采用了一种经验方法,使γ随模拟小肠浓度变化。将计算机模拟预测结果与已发表的不同剂量AZD0865的人体体内血浆药物浓度数据以及甲苯达唑的犬肠道药物浓度、肠道沉淀量和血浆浓度进行了比较。结果表明,该模型药物AZD0865在高达4 mg/kg剂量时对人体吸收缺乏显著的结晶影响,这与体内数据一致。该模型也很好地描述了犬类中甲苯达唑的肠道沉淀情况,预测的平均沉淀量为实测固体量的136%(范围为111 - 164%),预测的平均肠道浓度为实测浓度的94%(范围为59 - 147%)。总之,体外-计算机模拟方法可用于预测结晶对吸收的影响,但该模型在理论结晶模型和体外实验设计方面的进一步开发工作将使其受益。